This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2008 Mar 22;371(9617):983; author reply 984-5.

doi: 10.1016/S0140-6736(08)60443-2.

Treatment for elderly patients with multiple myeloma

Masaharu Tsubokura, Masahiro Kami

PMID: 18358919
DOI: 10.1016/S0140-6736(08)60443-2

Comment

Treatment for elderly patients with multiple myeloma

Masaharu Tsubokura et al. Lancet. 2008.

. 2008 Mar 22;371(9617):983; author reply 984-5.

doi: 10.1016/S0140-6736(08)60443-2.

Authors

Masaharu Tsubokura, Masahiro Kami

PMID: 18358919
DOI: 10.1016/S0140-6736(08)60443-2

No abstract available

PubMed Disclaimer

Comment on

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-Loiseau H; Intergroupe Francophone du Myélome. Facon T, et al. Lancet. 2007 Oct 6;370(9594):1209-18. doi: 10.1016/S0140-6736(07)61537-2. Lancet. 2007. PMID: 17920916 Clinical Trial.

Similar articles

[Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients].
Mellstedt H, Gimsing P, Waage A. Mellstedt H, et al. Lakartidningen. 2011 Oct 19-25;108(42):2090-4. Lakartidningen. 2011. PMID: 22165535 Review. Swedish. No abstract available.
[Multiple myeloma -- therapy].
Jung W, Zettl F, Schroers R. Jung W, et al. Dtsch Med Wochenschr. 2005 Feb 11;130(6):283-6; quiz 287-90. doi: 10.1055/s-2005-837415. Dtsch Med Wochenschr. 2005. PMID: 15692903 German. No abstract available.
Novel agents for relapsed and/or refractory multiple myeloma.
Thomas SK, Richards TA, Weber DM. Thomas SK, et al. Cancer J. 2009 Nov-Dec;15(6):485-93. doi: 10.1097/PPO.0b013e3181c51cba. Cancer J. 2009. PMID: 20010168 Review.
Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.
Prince HM, Schenkel B, Mileshkin L. Prince HM, et al. Leukemia. 2007 Apr;21(4):818-20; author reply 821. doi: 10.1038/sj.leu.2404573. Epub 2007 Feb 15. Leukemia. 2007. PMID: 17301817 No abstract available.
Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Badros A, Gahres N. Badros A, et al. Clin Adv Hematol Oncol. 2005 Dec;3(12):916-7; discussion 918. Clin Adv Hematol Oncol. 2005. PMID: 16555432 No abstract available.

See all similar articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information